竹下 梢 (タケシタ コズエ)

Takeshita, Kozue

写真a

所属(所属キャンパス)

医学部 微生物学・免疫学教室 (信濃町)

職名

助教(有期)

学位 【 表示 / 非表示

  • 医学博士, 慶応義塾大学医学部大学院

 

論文 【 表示 / 非表示

  • Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation

    Yoshifuji K., Inamoto K., Kiridoshi Y., Takeshita K., Sasajima S., Shiraishi Y., Yamashita Y., Nisaka Y., Ogura Y., Takeuchi R., Toya T., Igarashi A., Najima Y., Doki N., Kobayashi T., Ohashi K., Suda W., Atarashi K., Shiota A., Hattori M., Honda K., Kakihana K.

    Blood Advances (Blood Advances)  4 ( 19 ) 4607 - 4617 2020年10月

    ISSN  24739529

     概要を見る

    © 2020 by The American Society of Hematology Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563.

  • A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

    Tanoue T., Morita S., Plichta D.R., Skelly A.N., Suda W., Sugiura Y., Narushima S., Vlamakis H., Motoo I., Sugita K., Shiota A., Takeshita K., Yasuma-Mitobe K., Riethmacher D., Kaisho T., Norman J.M., Mucida D., Suematsu M., Yaguchi T., Bucci V., Inoue T., Kawakami Y., Olle B., Roberts B., Hattori M., Xavier R.J., Atarashi K., Honda K.

    Nature (Nature)  565 ( 7741 ) 600 - 605 2019年01月

    ISSN  00280836

     概要を見る

    © 2019, Springer Nature Limited. There is a growing appreciation for the importance of the gut microbiota as a therapeutic target in various diseases. However, there are only a handful of known commensal strains that can potentially be used to manipulate host physiological functions. Here we isolate a consortium of 11 bacterial strains from healthy human donor faeces that is capable of robustly inducing interferon-γ-producing CD8 T cells in the intestine. These 11 strains act together to mediate the induction without causing inflammation in a manner that is dependent on CD103 + dendritic cells and major histocompatibility (MHC) class Ia molecules. Colonization of mice with the 11-strain mixture enhances both host resistance against Listeria monocytogenes infection and the therapeutic efficacy of immune checkpoint inhibitors in syngeneic tumour models. The 11 strains primarily represent rare, low-abundance components of the human microbiome, and thus have great potential as broadly effective biotherapeutics.

  • Fecal microbiota transplantation with frozen capsules for a patient with refractory acute gut graft-versus-host disease

    Kaito S., Toya T., Yoshifuji K., Kurosawa S., Inamoto K., Takeshita K., Suda W., Kakihana K., Honda K., Hattori M., Ohashi K.

    Blood Advances (Blood Advances)  2 ( 22 ) 3097 - 3101 2018年11月

    ISSN  24739529

  • Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis

    Nanki K., Mizuno S., Matsuoka K., Ono K., Sugimoto S., Kiyohara H., Arai M., Nakashima M., Takeshita K., Saigusa K., Senoh M., Fukuda T., Naganuma M., Kato H., Suda W., Hattori M., Kanai T.

    Intestinal Research (Intestinal Research)  16 ( 1 ) 142 - 146 2018年

    ISSN  15989100

     概要を見る

    © 2018. Korean Association for the Study of Intestinal Diseases. Fecal microbiota transplantation (FMT) has been reported as a safe and effective therapy in patients with refractory and recurrent Clostridium difficile infection (CDI). FMT has also been reported as a promising therapy in patients with ulcerative colitis (UC). Both, CDI and UC, are believed to be caused by dysbiosis, such as altered compositions or decreased diversity of the intestinal microbiota. This report describes a patient with UC in remission with a second recurrent episode of CDI, who was treated with FMT. A single FMT performed via colonoscopy completely resolved the patient's diarrhea and eradicated C. difficile bacteriologically without any severe complications. Molecular biological analysis of the patient's fecal microbiota showed that FMT could dramatically change the altered composition of intestinal microbiota and restore its diversity. Despite the restoration of the intestinal microbiota, FMT could not prevent a relapse of UC in this patient. However, it improved the intestinal symptoms of CDI and could prevent further recurrences of CDI.

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

 

担当授業科目 【 表示 / 非表示

  • 微生物学

    2021年度

  • 微生物学

    2020年度

  • 微生物学

    2019年度